Latest Safety News

FBR Limited has secured a pivotal engineering agreement with Samsung Heavy Industries to develop a shipbuilding automation robot, marking a significant step in industrial robotics innovation.

Aurizon has landed a major 15-year contract to manage BHP’s Copper South Australia logistics, investing $100 million in new infrastructure and promising a greener, safer transport solution.

Toubani Resources has initiated a 5,000-metre diamond drilling campaign at its Kobada Gold Project in Mali, targeting deeper mineralisation to expand its 2.2 million ounce resource and extend mine life.

Nyrada’s Phase I clinical trial for its novel drug Xolatryp has cleared safety reviews through four cohorts and will now test higher doses and longer infusions in an expanded trial design.

Amplia Therapeutics has reported a rare pathological complete response in a patient from its ACCENT trial, highlighting promising potential for its drug narmafotinib in treating advanced pancreatic cancer.

Syntara Limited has unveiled encouraging interim Phase 2a data for SNT-5505, an add-on therapy targeting myelofibrosis patients with suboptimal response to ruxolitinib. The data highlight meaningful symptom relief and spleen volume reduction, positioning the drug as a potential game-changer in a challenging treatment landscape.

Clarity Pharmaceuticals’ novel PET imaging agent Cu-SAR-Bombesin demonstrated safety and effectiveness in detecting prostate cancer recurrence missed by standard scans in its Phase II SABRE trial. The agent identified lesions in about one-third of patients with negative or equivocal standard imaging.

Invion Limited launches a Loyalty Option entitlement offer aimed at raising up to $16 million to support its advancing cancer clinical trials, including a promising anogenital cancer study with Peter MacCallum Cancer Centre.

Macarthur Minerals has relaunched a renounceable rights issue to raise nearly A$2 million, fully underwritten by Gold Valley, aiming to fund its Lake Giles Iron Project and strengthen its balance sheet.

Dimerix has reached a key milestone by dosing 200 adult patients in its Phase 3 ACTION3 trial for FSGS, progressing steadily toward full recruitment expected in late 2025.

Syntara Limited reports encouraging interim Phase 2 data for its drug SNT-5505 combined with ruxolitinib, demonstrating significant symptom relief and spleen volume reduction in myelofibrosis patients. The company plans to engage the FDA soon to discuss pivotal trial design.

NexGen Energy has secured regulatory approval for a significant infrastructure upgrade at its Rook I uranium project, setting the stage for expanded exploration and operational efficiency in 2025.